You are here

nhibition the malignancy of tumor cells as a way to improve therapy of cancer patients

Work number - M 29 AWARDED

Author: N. Bezdenezhnykh

Presented by the RE.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine

In this paper solved an important scientific problem modifying the phenotype of tumor cells to the downside of malignancy, which resulted in opening up new possibilities of increasing the effectiveness of treatment patients with malignant tumors.

Developed the scientific principles and methods of use of interferon as part of biotherapy in the schemes of combined treatment of cancer. The expediency of use of a long course of Interferon in oncological practice, not only as an immunomodulatory agent, but also as a means of broad anti-tumor properties.Received fundamental data that reveal the mechanisms of increaseby  interferon the sensitivity of tumor cells to anticancer drugs of different origins, which opens prospects for its use in the treatment regimens of patients with cancer, alsoin metronomic  regimens.

Developed and implemented approaches to the inhibition of tumor cell malignancy using as a modifier interferon. In particular, for the first time demonstrated the role of cytokines as an inhibitor of epithelial-mesenchymal transition of tumor cells. On a global level developments indicate high prevalence of the use of interferon as an antitumor and immunomodulatory cytokine in complex treatment regimens in patients with cancer.

The economic effect of the introduction: opening of new mechanisms of action of known cytokine and its use as an inhibitor of the malignant phenotype of tumor cells opens new possibilities for the use of interferon in the treatment of cancer patients as an anticancer product with low cost. The said will increase the effectiveness of treatment and improve the quality of life of cancer patients.

Research results are shown in 14 articles. Novelty of and competitiveness of technical decisions protected by patent and application acts. The work of the author cited in more than 13 scientific journals:by Google Scholar - 34, BioInfoBank Library - 4, Web of Science - 7, h-index (Scopus) - 3.

The total number of publications of the author:  101.